silicon phthalocyanine pc4 has been researched along with erlotinib hydrochloride in 1 studies
| Studies (silicon phthalocyanine pc4) | Trials (silicon phthalocyanine pc4) | Recent Studies (post-2010) (silicon phthalocyanine pc4) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 113 | 1 | 63 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | silicon phthalocyanine pc4 (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JJ; Huang, YZ; Song, MR; Xue, JP; Zhang, ZH | 1 |
1 other study(ies) available for silicon phthalocyanine pc4 and erlotinib hydrochloride
| Article | Year |
|---|---|
Silicon Phthalocyanines Axially Disubstituted with Erlotinib toward Small-Molecular-Target-Based Photodynamic Therapy.
Topics: Antineoplastic Agents; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Indoles; Light; Liver Neoplasms; Microscopy, Confocal; Organosilicon Compounds; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Reactive Oxygen Species; Zinc | 2017 |